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Abstract Creatine deficiency syndromes, due to defi-
ciencies in AGAT, GAMT (creatine synthesis pathway) or
SLC6A8 (creatine transporter), lead to complete absence or
very strong decrease of creatine in CNS as measured by
magnetic resonance spectroscopy. Brain is the main organ
affected in creatine-deficient patients, who show severe
neurodevelopmental delay and present neurological
symptoms in early infancy. AGAT- and GAMT-deficient
patients can be treated by oral creatine supplementation
which improves their neurological status, while this treat-
ment is inefficient on SLC6A8-deficient patients. While it
has long been thought that most, if not all, of brain creatine
was of peripheral origin, the past years have brought evi-
dence that creatine can cross blood–brain barrier, however,
only with poor efficiency, and that CNS must ensure parts
of its creatine needs by its own endogenous synthesis.
Moreover, we showed very recently that in many brain
structures, including cortex and basal ganglia, AGAT and
GAMT, while found in every brain cell types, are not co-
expressed but are rather expressed in a dissociated way.
This suggests that to allow creatine synthesis in these
structures, guanidinoacetate must be transported from
AGAT- to GAMT-expressing cells, most probably through
SLC6A8. This new understanding of creatine metabolism
and transport in CNS will not only allow a better com-
prehension of brain consequences of creatine deficiency
syndromes, but will also contribute to better decipher
creatine roles in CNS, not only in energy as ATP
regeneration and buffering, but also in its recently sug-
gested functions as neurotransmitter or osmolyte.
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Introduction
The creatine (Cr)/phosphocreatine (PCr)/creatine kinase
(CK) system plays essential roles in maintaining the high
energy levels necessary for brain development and func-
tions, through regeneration and buffering of ATP levels
(Wallimann et al. 1992, 2007; Wyss and Kaddurah-Daouk
2000; Brosnan and Brosnan 2007; Andres et al. 2008).
Recent works suggest that creatine in CNS may also act as
true neurotransmitter and one of the main CNS osmolytes
(Bothwell et al. 2002; Almeida et al. 2006). In mammals,
half of Cr is obtained from diet, the other half being syn-
thesized endogenously by a two-step mechanism involving
L-arginine:glycine amidinotransferase (AGAT) and guani-
dinoacetate methyltransferase (GAMT). Cr is distributed
by blood to tissues and taken up by cells through a specific
Cr transporter, SLC6A8, also abbreviated CT1, CRTR,
CTR or CreaT (Wyss and Kaddurah-Daouk 2000).
Cr deficiency syndromes are caused by mutations in
AGAT, GAMT and SLC6A8 genes (Sto¨ckler et al. 1994;
Salomons et al. 2001; Item et al. 2001). Their common
phenotype is an almost complete lack of Cr in CNS, as
measured by magnetic resonance spectroscopy (MRS),
CNS appearing as the main organ affected in these primary
Cr deficiencies. Patients develop severe neurodevelop-
mental delay and present neurological symptoms in early
infancy, such as mental retardation, delays in speech
acquisition or epilepsy (Sto¨ckler et al. 2007). Oral Cr
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supplementation strongly improves the neurological status
of AGAT- and GAMT-deficient patients (Sto¨ckler et al.
1996; Schulze et al. 1998; Battini et al. 2002; Schulze and
Battini 2007), while this treatment is inefficient on
SLC6A8-deficient patients (Bizzi et al. 2002; Po´o-Argu¨-
elles et al. 2006; Arias et al. 2007). Secondary Cr defi-
ciencies are also observed in other pathological states of
the brain, like stroke, hyperammonemic states or gyrate
atrophy of the choroid and retina (GA) (Valle et al. 1981;
Braissant et al. 2008; Lei et al. 2009).
It has long been thought that most, if not all, cerebral Cr
was of peripheral origin (Wyss and Kaddurah-Daouk
2000). However, AGAT and GAMT are expressed in CNS
and brain cells synthesize their own Cr (Braissant et al.
2001b; Braissant et al. 2002). In contrast, while SLC6A8 is
expressed by microcapillary endothelial cells (MCEC) at
blood–brain barrier (BBB), allowing CNS to import Cr
from periphery, it is absent from astrocytes, at least in
physiological conditions, and particularly from their feet
lining MCEC (Fig. 1; Braissant et al. 2001b; Ohtsuki et al.
2002; Tachikawa et al. 2004). This made us suggest that
BBB has a limited permeability for peripheral Cr and that
CNS must supply an important part of its Cr needs by
endogenous synthesis rather than on an exclusive supply
from the blood (Braissant et al. 2001b; Braissant and Henry
2008). Similar to periphery with predominant expression of
AGAT in kidney and GAMT in liver (Edison et al. 2007;
da Silva et al. 2009), recent data also suggest that the Cr
synthesis pathway may be dissociated in CNS, guanidino-
acetate (GAA) being transported through SLC6A8 from
Fig. 1 Creatine synthesis and transport in central nervous system:
model illustrating endogenous synthesis versus uptake from periph-
ery, including the various combinations of AGAT, GAMT and
SLC6A8 expression within brain cells (Braissant et al. 2010). (1) Cr
endogenous synthesis within cells co-expressing AGAT and GAMT.
(2) Cr endogenous synthesis through AGAT-expressing cells synthe-
sizing GAA, and GAA uptake by SLC6A8 in GAMT-expressing
cells; this conformation appears the prevalent one in most brain
regions. (3) Cells expressing only SLC6A8 (‘‘users’’ of Cr). (4) Cells
silent for AGAT, GAMT and SLC6A8. While microcapillaries
express SLC6A8, astrocytic feet lining them do not. This implies that
only low amounts of peripheral Cr can enter the brain through the
limited endothelial surface that is free of astrocytic feet and that CNS
must also ensure its own endogenous synthesis of Cr. So far, the way
Cr (and GAA) can leave cells is poorly known. Cr: creatine; AGAT:
L-arginine:glycine amidinotransferase; GAMT: guanidinoacetate
methyltransferase; GAA: guanidinoacetate; SLC6A8: Cr transporter
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AGAT- to GAMT-expressing cells to allow synthesis of Cr
in the brain (Braissant et al. 2010).
This review is focused on Cr deficiency syndromes and
their effects on the brain in view of the latest data on Cr
synthesis and transport in CNS, in order to delineate a
comprehensive frame on Cr metabolism and transport in
CNS, both in normal and Cr-deficient conditions.
Creatine deficiency syndromes
CNS is the main organ affected in patients suffering from
the Cr deficiency syndromes, inborn errors of Cr biosyn-
thesis and transport caused by AGAT, GAMT or SLC6A8
deficiency which are characterized by an absence or a
severe decrease of Cr in CNS as measured by MRS
(Sto¨ckler et al. 1994; Salomons et al. 2001; Item et al.
2001). AGAT and GAMT deficiencies are autosomal
recessive diseases, while SLC6A8 deficiency is an
X-linked disorder. Cr deficiency syndromes appear among
the most frequent inborn errors of metabolism (IEM), the
prevalence of SLC6A8 deficiency being estimated at 2% of
all X-linked mental retardations (Rosenberg et al. 2004)
and at 1% of males with mental retardation of unknown
etiology (Clark et al. 2006). AGAT and GAMT deficien-
cies are rarer, but the prevalence of all combined Cr defi-
ciencies was estimated between 0.3% and 2.7% of all
mental retardation (Lion-Franc¸ois et al. 2006; Arias et al.
2007).
Cr-deficient patients present neurological symptoms in
infancy (Schulze et al. 1997; Battini et al. 2002; DeGrauw
et al. 2002). In particular, mental retardation and delays in
speech acquisition can be observed (AGAT, GAMT and
SLC6A8 deficiencies), as well as intractable epilepsy
(GAMT and SLC6A8 deficiencies), autism, automutilating
behavior, extrapyramidal syndrome and hypotonia (GAMT
deficiency) (Sto¨ckler et al. 2007). The diverse phenotypic
spectrum of neurological symptoms observed in AGAT-,
GAMT- and SLC6A8-deficient patients shows the impor-
tance of Cr for psychomotor development and cognitive
functions and is probably explained by the wide pattern of
AGAT, GAMT and SLC6A8 expression in the mammalian
brain (see below). The recently proposed roles of Cr as co-
transmitter on GABA postsynaptic receptors (Almeida
et al. 2006) and of regulator of appetite and weight on
specific hypothalamic nuclei (Galbraith et al. 2006) might
also contribute to this phenotypic diversity. The more
complex phenotype of GAMT deficiency, including
intractable epilepsy, extrapyramidal movement syndromes
and abnormalities in basal ganglia is probably due to the
toxicity, and particularly the epileptogenic action, of brain
GAA accumulation characteristic of GAMT deficiency
(Schulze et al. 2001), which may occur through activation
of GABAA receptors by GAA (Neu et al. 2002). GAA may
also inhibit the complex between Na?/K?-ATPase and CK
(Zugno et al. 2006). Severe epilepsy may also appear in
SLC6A8-deficient patients (Mancardi et al. 2007). This
may be due to the observed CNS GAA accumulation in
some SLC6A8-deficient patients (Sijens et al. 2005), which
could be caused by impairment of GAA transport through
deficient SLC6A8, from AGAT- to GAMT-expressing
brain cells (see below) (Braissant et al. 2010).
Treatments and outcome of Cr deficiency syndromes
AGAT- and GAMT-deficient patients can be treated by
oral supplementation of Cr. While this strongly improves
their neurological status and CNS development, very high
doses of Cr must be used, and replenishment of cerebral Cr
takes months and only results, in most cases, in partial
restoration of cerebral Cr pools (Sto¨ckler et al. 1996;
Ganesan et al. 1997; Item et al. 2001; Battini et al. 2002).
For GAMT-deficient patients, combined arginine restric-
tion and ornithine substitution coupled with Cr treatment
decreases GAA and also improves clinical outcome
(Schulze et al. 1998, 2001). Despite improvement of clin-
ical outcome by Cr supplementation, many AGAT- and
GAMT-deficient patients remain with CNS developmental
problems. However, the pre-symptomatic treatment of
AGAT- and GAMT-deficient patients appears to prevent,
so far, most of the Cr-deficiency effects on their brain
(Battini et al. 2006; Schulze et al. 2006; Schulze and
Battini 2007). Oral supplementation of Cr is inefficient in
replenishing brain Cr in SLC6A8-deficient patients, who
remain with mental retardation, severe speech impairment
and progressive brain atrophy (Cecil et al. 2001; Bizzi et al.
2002; DeGrauw et al. 2002; Po´o-Argu¨elles et al. 2006).
Attempts to treat SLC6A8-deficient patients with arginine
as precursor of Cr also failed to improve their neurological
status (Fons et al. 2008). Similarly, the use of a lipophilic
Cr-derived compound, creatine ethyl ester, failed to
replenish brain Cr concentration in SLC6A8-deficient
patients, as well as to improve their neurological status
(Fons et al. 2010).
Secondary creatine deficiencies in CNS
Several other CNS pathologies that cause a secondary Cr
deficiency in brain cells have been identified. Excess of
ammonium (NH4
?) is toxic for CNS. In pediatric patients,
hyperammonemia can be caused by various acquired or
inherited disorders, the most frequent being urea cycle
diseases, which can cause irreversible damages to the
developing brain (Leonard and Morris 2002) by altering
Importance of creatine synthesis in the brain 1317
123
several amino acid pathways and neurotransmitter systems,
nitric oxide synthesis, axonal and dendritic growth and
signal transduction pathways (Cagnon and Braissant 2007,
2008, 2009) eventually leading to energy deficit, oxidative
stress and cell death (Braissant 2010b). In particular, NH4
?
exposure generates a secondary Cr deficiency in brain cells
(Ratnakumari et al. 1996; Choi and Yoo 2001; Braissant
et al. 2002). NH4
? appears to inhibit AGAT enzymatic
activity and differentially alters AGAT, GAMT and
SLC6A8 gene expression in a cell type-specific manner,
which may alter the energy requirements of brain cells
(Braissant et al. 2008; Braissant 2010a). Ischemic stroke in
CNS leads to a rapid diminution in brain total Cr
(Cr ? PCr) (Obrenovitch et al. 1988; Gideon et al. 1992;
Mathews et al. 1995; Lei et al. 2009). This lower Cr level
in stroke causes a decrease in high-energy phosphate pro-
duction and leads to a failure in most energy-dependent
processes necessary for cell survival. Gyrate atrophy of the
choroid and retina (GA) is an inborn error of metabolism
leading to blindness in the first 10 years of life and is
caused by mutations in ornithine d-aminotransferase
(OAT) (Valle et al. 1981). OAT deficiency generates a
secondary Cr deficiency, as it generates an important
ornithine accumulation facilitating the reversed AGAT
reaction, therefore depleting GAA for Cr synthesis (Sipila¨
1980). This is particularly true in CNS, where GA neuro-
logical symptoms may be related to this secondary Cr
deficiency (Na¨nto¨-Salonen et al. 1999; Valayannopoulos
et al. 2009).
AGAT, GAMT and SLC6A8 in CNS
Cr is synthesized in the mammalian brain (Pisano et al.
1963; Van Pilsum et al. 1972), in nerve cell lines as well as
in primary and organotypic brain cell cultures (Daly 1985;
Dringen et al. 1998; Braissant et al. 2002). AGAT and
GAMT are expressed in CNS, where they are found in all
the main structures of the brain, in every main cell types
(neurons, astrocytes and oligodendrocytes, Fig. 1; Brais-
sant et al. 2001b; Tachikawa et al. 2004; Schmidt et al.
2004; Nakashima et al. 2005). Moreover, we have shown
very recently that in most regions of the rat brain, AGAT
and GAMT are rarely co-expressed within the same cell
(see below; Braissant et al. 2010). Organotypic rat cortical
cultures, primary brain cell cultures (neuronal, glial or
mixed) and neuroblastoma cell lines have a Cr transporter
activity (Mo¨ller and Hamprecht 1989; Almeida et al. 2006;
Braissant et al. 2008). In vivo, mouse and rat CNS can take
up Cr from the blood against its concentration gradient
(Ohtsuki et al. 2002; Perasso et al. 2003). SLC6A8 is
expressed throughout the main regions of adult mammalian
brain (Schloss et al. 1994; Happe and Murrin 1995;
Braissant et al. 2001b; Tachikawa et al. 2008; Mak et al.
2009). In the first detailed analyses of Cr transporter
expression in CNS, it was demonstrated that SLC6A8 is
found in neurons and oligodendrocytes but, in contrast to
AGAT and GAMT, cannot be detected in astrocytes
(Fig. 1; Braissant et al. 2001b), except for very rare ones in
cerebellum (Mak et al. 2009). This holds true also for the
retina, where SLC6A8 is expressed in retinal neurons, but
not in astrocytes (Nakashima et al. 2004; Acosta et al.
2005). In contrast to its absence in astrocytes lining mi-
crocapillaries, SLC6A8 is present in MCEC making BBB
(Braissant et al. 2001b; Ohtsuki et al. 2002; Tachikawa
et al. 2004).
It must be emphasized also that AGAT, GAMT and
SLC6A8 are expressed very differently by brain cells,
depending on whether the analysis is made in vivo or in
vitro, as well as in vitro depending on the type of cultures.
20 years ago, an important paper by Mo¨ller and Hamprecht
showed a detailed description of the in vitro Cr uptake
capacity of numerous types of primary brain cells, as well
as immortalized cell lines, all cultured in the presence of
serum. They concluded that astrocytes have the highest
activity of Cr transporter (Mo¨ller and Hamprecht 1989).
We showed that in vivo AGAT and GAMT can be found in
all brain cell types, while, in contrast to what was dem-
onstrated in primary cultures of astrocytes, SLC6A8 is not
expressed by astrocytes (Braissant et al. 2001b). We further
demonstrated that organotypic cultures such as brain 3D
mixed-cell aggregates cultured in the absence of serum
synthesize their own Cr and express AGAT, GAMT and
SLC6A8 as the in vivo CNS, including the absence of
SLC6A8 from astrocytes (Braissant et al. 2008). In con-
trast, when we analyzed brain 3D neuron-enriched aggre-
gates also cultured in the absence of serum, from which
astrocytes and oligodendrocytes have been eliminated, we
showed that in the absence of glial cells, AGAT and
GAMT are totally silent from neurons and from the very
few remaining astrocytes, while both genes are well
expressed in both cell types when glial cells are present
(Braissant et al. 2008). It is known that brain cells cultured
as 2D monolayers or in the presence of serum develop a
pathological reactive state that completely alters their
behavior in terms of gene expression and protein activities.
This is particularly true for astrocytes, which develop
constant reactive gliosis as illustrated by their increase in
GFAP and vimentin expression as compared with in vivo
conditions (Langan and Slater 1992; F.Tschudi-Monnet
and P.Honegger, personal communication; and unpub-
lished results). We have shown that SLC6A8, which is
silent in astrocytes in vivo as well as in 3D brain cells
aggregates cultured in the absence of serum, is activated in
these same astrocytes when they are placed in a reactive
state (in that case exposure to ammonium; Cagnon and
1318 O. Braissant et al.
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Braissant 2007; Braissant et al. 2008; Braissant 2010b). It
appears, thus, that most models of cultured brain cells, in
particular when cultured in the presence of serum, do not
behave as the in vivo CNS for Cr metabolism and transport.
Thus, to analyze Cr in brain cells in conditions as near as
possible of the in vivo CNS, complex 3D, organotypic and
mixed-cell culture systems in the absence of serum should
be used (Braissant 2010a).
Creatine in CNS: endogenous synthesis versus uptake
from periphery?
The in vivo expression of AGAT and GAMT within
mammalian CNS, as well as the in vitro endogenous syn-
thesis of Cr by various types of cultured brain cells,
including primary and organotypic cultures, suggest that
brain synthesizes Cr (Braissant et al. 2007). However, it
was thought for a long time that most, if not all, of the Cr
needed by CNS comes from periphery through BBB (Wyss
and Kaddurah-Daouk 2000).
The discovery that SLC6A8 cannot be detected in
astrocytes, particularly in their feet sheathing MCEC made
us suggest, however, that in mature CNS, BBB has a
limited permeability for Cr, despite SLC6A8 expression by
MCEC and their capacity to import Cr (Braissant et al.
2001b; Ohtsuki et al. 2002; Tachikawa et al. 2004; Naka-
shima et al. 2004; Acosta et al. 2005). In vivo data con-
firmed this hypothesis: the blood to brain transport of Cr
through BBB is effective in rats and mice but is relatively
inefficient (Ohtsuki et al. 2002; Perasso et al. 2003), and
long-term treatment of AGAT- and GAMT-deficient
patients with high doses of Cr allows only a slow and in
most cases partial replenishment of their brain Cr pools
(Sto¨ckler et al. 2007; Schulze and Battini 2007). Similarly,
GAMT-/- KO mice treated with high doses of Cr replenish
their brain Cr, but only slowly (Kan et al. 2007). The
effective but limited entry of Cr from blood to CNS
through MCEC but without going through astrocytes may
occur through the limited surface of CNS microcapillary
endothelium that is free of astrocytic feet (Fig. 1; Virgin-
tino et al. 1997; Ohtsuki 2004).
One strong argument in favor of the ‘‘brain endogenous
Cr synthesis’’ hypothesis comes from Cr measures in the
CSF of Cr-deficient patients (see Braissant and Henry
2008, and references therein). SLC6A8-deficient patients
present normal Cr levels in CSF, but are strictly unable to
import Cr from periphery (Cecil et al. 2001; DeGrauw
et al. 2002; Bizzi et al. 2002; Po´o-Argu¨elles et al. 2006).
In contrast, GAMT-deficient patients show strongly
decreased levels of Cr in CSF but are able to import Cr
from the blood (Sto¨ckler et al. 1994; Schulze et al. 1997).
This also suggests that Cr synthesis in the brain might still
remain operational, although very partially, under
SLC6A8 deficiency, while it is completely blocked in
AGAT and GAMT deficiencies. Endogenous synthesis or
a very efficient uptake from the periphery are the two
ways available for the brain to secure Cr homeostasis for
its energy and functions. As uptake from the periphery
does not appear efficient, CNS might privilege Cr
endogenous synthesis. The brain capacity for Cr synthesis
would thus depend on the efficient supply of arginine, the
limiting substrate for Cr synthesis, from blood to CNS,
and then also on local trafficking of arginine between
brain cells. We and others have shown that cationic amino
acid transporters (CATs) might fulfill these roles in the
brain, as CAT1 is expressed in MCEC as well as ubiq-
uitously in neuronal and glial cells, as CAT2(B) is present
in neurons and oligodendrocytes, and as CAT3 is restric-
ted to neurons (Braissant et al. 1999; Hosokawa et al.
1999; Braissant et al. 2001a).
The hypothesis of endogenous Cr synthesis in the brain
might seem to contradict the in vivo characteristics of
SLC6A8 deficiency, which, despite AGAT and GAMT
expression in CNS, presents an absence (or a very low
level) of brain Cr by MRS (Salomons et al. 2001). This
apparent contradiction is probably explained by our very
recent data on AGAT, GAMT and SLC6A8 expression
patterns in the brain. AGAT and GAMT are found in every
CNS cell type (Braissant et al. 2001b), but appear rarely
co-expressed within the same cell (Braissant et al. 2010).
This suggests that to allow Cr synthesis in the brain, GAA
must be transported from AGAT- to GAMT-expressing
cells (Fig. 1). This GAA transfer most probably occurs
through SLC6A8, as shown in the same study by Cr and
GAA competition studies and the use of stable isotope-
labeled GAA demonstrating its uptake by brain cells fol-
lowed by its conversion to Cr by GAMT activity (Braissant
et al. 2010). These observations may explain the absence of
Cr in CNS of SLC6A8-deficient patient, despite normal
expression of AGAT and GAMT in their brain (Braissant
and Henry 2008), as well as the lack of effect of treatment
of SLC6A8-deficient patients with arginine as a precursor
of Cr (Fons et al. 2008). Recent studies also demonstrated
the potential role of SLC6A8 (and taurine transporter) for
GAA transport across BBB and in brain parenchymal cells
(Tachikawa et al. 2008, 2009).
While we have shown that AGAT and GAMT can be
found in all brain cell types (Braissant et al. 2001b), other
studies demonstrated particularly high levels of GAMT in
glial cells (Schmidt et al. 2004; Tachikawa et al. 2004;
Braissant et al. 2008), suggesting that the final CNS step
for Cr synthesis may predominantly be glial. However, this
probably depends on the brain region considered, as in
cortex only 20% of astrocytes express GAMT in compar-
ison with 48% of neurons (Braissant et al. 2010).
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Adult versus developmental CNS
As described above, the adult (or mature) brain might
privilege Cr endogenous synthesis versus uptake from
periphery, due to low permeability of BBB for Cr and the
expression of AGAT and GAMT in CNS parenchyma.
Fetal and perinatal (or immature) CNS probably behaves
differently for its Cr needs.
The Cr/PCr/CK system plays essential roles in energy
homeostasis during vertebrate embryonic development
(Wallimann et al. 1992), the fetal needs in Cr being partly
supported by active transport of Cr from mother to fetus
(Davis et al. 1978; Ireland et al. 2008). On the other hand,
AGAT, GAMT and SLC6A8 are also well expressed dur-
ing vertebrate embryogenesis, including in the brain
(Schloss et al. 1994; Sandell et al. 2003; Schmidt et al.
2004; Braissant et al. 2005; Wang et al. 2007; Ireland et al.
2009). We have shown that AGAT and GAMT are
expressed in the whole developing CNS parenchyma
(Braissant et al. 2005). However, their low level (GAMT in
particular) at early developmental stages suggests that in
contrast to adult brain, embryonic CNS depends predomi-
nantly on external Cr supply, be it from embryonic
periphery or from maternal origin. This is coherent with
SLC6A8 expression in the whole embryonic CNS already
at early stages (E12.5 in rat), with particularly high levels
in the periventricular zone and choroid plexus, the pre-
dominant metabolic exchange zones of fetal CNS before
microcapillary angiogenesis and differentiation of BBB
(Braissant et al. 2005, 2007).
Creatine and guanidinoacetate within normal
versus creatine-deficient CNS
In normal conditions, Cr within human CSF is maintained
in the 17–90 lM range, while GAA is maintained at a
10009 lower level (0.015–0.114 lM). By MRS, total Cr is
measured between 5.5 and 6.4 mM in the cortical gray
matter, while GAA was estimated to 1.6 mM (see Braissant
and Henry 2008, and references therein).
With the exception of SLC6A8-deficient heterozygous
females where brain Cr deficiency is partial (Cecil et al.
2003), all three Cr deficiencies present the virtual absence
of the Cr peak measured by MRS in cortex and basal
ganglia (Sto¨ckler et al. 2007). However, despite this lack of
Cr detection by MRS, Cr remains present within the brain
of Cr-deficient patients. In SLC6A8 deficiency, Cr CSF
levels do not differ from age-matched controls (Cecil et al.
2001; Salomons et al. 2001; DeGrauw et al. 2002). In
AGAT deficiency, total Cr levels in cortical gray matter are
decreased to 12% of age-matched controls (Battini et al.
2002). In GAMT deficiency, CSF Cr levels are strongly
decreased (\2 lM) (Schulze et al. 1997, 2003; Ensenauer
et al. 2004), while in cortical gray matter total Cr was
measured in the 0.2-1.5mM range (Sto¨ckler et al. 1994;
Mancini et al. 2005).
GAA accumulation in body fluids is characteristic of
GAMT deficiency, where its toxicity is responsible for the
more complex and specific phenotype of GAMT-deficiency
(see above). GAA CSF levels in GAMT-deficient patients
are 60–10009 higher than in age-matched controls, while
GAA was estimated to 3.6 mM within cortical gray matter.
No precise data are available on GAA levels within
AGAT- and SLC6A8-deficient CNS, but it was shown that
GAA can also accumulate in the brain of SLC6A8-defi-
cient patients (Sijens et al. 2005). As described above,
GAA may appear as a key intermediate player for endog-
enous Cr synthesis in CNS, as it must most probably be
transported from AGAT- to GAMT-expressing cells for Cr
synthesis to occur (Braissant et al. 2010), just as it does in
periphery between AGAT in kidney and GAMT in liver
(Edison et al. 2007; da Silva et al. 2009). It was recently
demonstrated that both BBB endothelial cells (Tachikawa
et al. 2009) and CNS parenchymal cells (Tachikawa et al.
2008; Braissant et al. 2010) are able to take up GAA by
SLC6A8. The Km value of SLC6A8 for GAA appears ten
times lower than that for Cr (Tachikawa et al. 2008). Thus,
entry of GAA into CNS in normal conditions must be
inhibited by blood Cr levels (1–3.5 lM for GAA versus
6–50 lM for Cr). This entry might, however, be facilitated
under GAMT deficiency, blood GAA levels becoming
higher than Cr levels (12–39 lM for GAA versus 1–5 lM
for Cr) (Almeida et al. 2004), therefore contributing to
GAA accumulation into the GAMT-deficient brain.
Models for creatine synthesis and trafficking in CNS
Taken together, (i) the absence of Cr within the brain of Cr-
deficient patients, (ii) the CNS expression patterns of
AGAT, GAMT and SLC6A8, (iii) the low permeability of
BBB for Cr and (iv) the measures of Cr and GAA within
CNS both in normal and Cr-deficient conditions, lead us to
propose the following model to understand Cr synthesis
and trafficking within the brain (Fig. 1) (Braissant and
Henry 2008):
In normal conditions, SLC6A8 is expressed by MCEC,
but not by the surrounding astrocytic feet, implying that
limited amounts of Cr can enter the brain through BBB. In
most brain regions (including cortex and basal ganglia,
where most MRS measures are performed), brain cells
express AGAT and GAMT in a cell-dissociated way, and
GAA must be transported from AGAT- to GAMT-
expressing cells by SLC6A8 for Cr synthesis to occur. In
AGAT and GAMT deficiency, no Cr can be synthesized
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within CNS, but SLC6A8 expression in MCEC allows the
limited entry of Cr within the brain and thus their treatment
by oral Cr and the partial replenishment of the brain Cr
pools. Moreover, the brain of GAMT-deficient patients
accumulates GAA. Cr transporter-deficient patients lack
functional SLC6A8 on MCEC and thus cannot be treated
by oral Cr. Moreover, their endogenous CNS Cr synthesis
pathway is also deficient, as in most brain regions, GAA
cannot cross from AGAT- to GAMT-expressing cells due
to their lack in functional SLC6A8.
Conclusion
Brain is the main organ affected in Cr deficiency syn-
dromes due to deficiencies in AGAT, GAMT or SLC6A8,
which lead to a complete absence or a very strong decrease
of Cr in CNS. AGAT- and GAMT-deficient patients can be
treated by oral creatine supplementation which improves
their neurological status, while this treatment is inefficient
on SLC6A8-deficient patients. The recent years have
brought new knowledge on Cr metabolism and transport in
the brain, allowing a better understanding on the patho-
physiology of Cr deficiency syndromes in brain cells. In
particular, there is evidence that BBB presents a low per-
meability for Cr and that CNS must ensure parts of its
needs in Cr by endogenous synthesis. Moreover, in many
regions of the brain, Cr endogenous synthesis appears to be
dissociated, GAA needing to be transported by SLC6A8
from AGAT- to GAMT-expressing cells for Cr synthesis to
occur. This probably explains why, despite AGAT and
GAMT expression in their brain, SLC6A8-deficient
patients remain with a Cr-depleted CNS.
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